{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:09:38Z","timestamp":1793257778229,"version":"4.5.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed\/refractory B-cell lymphomas, outcomes in these patients remain inferior to those of patients with B-cell leukemia, regardless of therapy. Recent clinical studies and preclinical reports suggest that certain characteristics, such as the suppressive lymphoma tumor microenvironment and inferior endogenous T-cell fitness, may contribute to discrepant responses in these patients. In addition, these studies revealed that limited CAR T-cell persistence and tumor antigen escape, which also impact B-cell acute lymphoblastic leukemia, may play a more prominent role in lymphoma. Multiple promising strategies to overcome these barriers have advanced to clinical trials. In this review, we assess CAR T-cell therapies for pediatric relapsed\/refractory mature B-cell lymphomas, potential obstacles diminishing antitumor activity and limiting CAR T-cell persistence, and current strategies to overcome these obstacles.<\/jats:p>","DOI":"10.1182\/hematology.2020000133","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:25:26Z","timestamp":1607138726000},"page":"487-493","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma"],"prefix":"10.1182","volume":"2020","author":[{"given":"Emily M.","family":"Hsieh","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX; and"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX; and"},{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2020121621255434600_B1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia [published correction appears in N Engl J Med. 2016;374(10):998]","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"9967","key":"2020121621255434600_B2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"2020121621255434600_B3","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020121621255434600_B4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621255434600_B5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621255434600_B6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"27","key":"2020121621255434600_B7","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020121621255434600_B8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2020121621255434600_B9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2020121621255434600_B10","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020121621255434600_B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2020121621255434600_B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas [abstract]","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621255434600_B13","doi-asserted-by":"crossref","first-page":"e22504","DOI":"10.1200\/JCO.2020.38.15_suppl.e22504","article-title":"Bianca: phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric\/young adult (YA) patients (Pts) with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL) [abstract]","volume":"38","author":"Minard","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621255434600_B14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR T cells induce a complete response in refractory Burkitt lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020121621255434600_B15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/hum.2015.054","article-title":"CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma","volume":"26","author":"Enblad","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"2","key":"2020121621255434600_B16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1189\/jlb.1203652","article-title":"Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination","volume":"76","author":"L\u00f3pez-Giral","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"18","key":"2020121621255434600_B17","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"2020121621255434600_B18","article-title":"Phase 1\/2 study of AUTO3 the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 followed by an anti-PD1 in patients with relapsed\/refractory (r\/r) diffuse large B cell lymphoma (DLBCL): results of cohort 1 and 2 of the Alexander study [abstract]","volume":"134","author":"Ardeshna","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2020121621255434600_B19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2020121621255434600_B20","first-page":"2825","article-title":"Marked re-expansion of chimeric antigen receptor (CAR) T cells and tumor regression following nivolumab treatment in a patient treated with axicabtagene ciloleucel (axi-cel; KTE-C19) for refractory diffuse large B cell lymphoma (DLBCL) [abstract]","volume":"130","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"2020121621255434600_B21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"2020121621255434600_B22","first-page":"TPS7572","article-title":"Zuma-6: phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL) [abstract]","volume-title":"J Clin Oncol","author":"Locke","year":"2017"},{"key":"2020121621255434600_B23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2018.00147","article-title":"The role of macrophage\/B-cell interactions in the pathophysiology of B-cell lymphomas","volume":"8","author":"Pham","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"2020121621255434600_B24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pin.12259","article-title":"Role of tumor-associated macrophages in hematological malignancies","volume":"65","author":"Komohara","year":"2015","journal-title":"Pathol Int"},{"issue":"10","key":"2020121621255434600_B25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"2020121621255434600_B26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2020121621255434600_B27","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2020121621255434600_B28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"issue":"17","key":"2020121621255434600_B29","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2020121621255434600_B30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V128.22.650.650","article-title":"Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL) [abstract]","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020121621255434600_B31","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"26","key":"2020121621255434600_B32","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2020121621255434600_B33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00432-020-03198-7","article-title":"Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review [published correction appears in J Cancer Res Clin Oncol. 2020;146(8):2177]","volume":"146","author":"Du","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"2020121621255434600_B34","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"2020121621255434600_B35","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression [published online ahead of print 24 March 2020]","author":"Fousek","journal-title":"Leukemia"},{"issue":"1","key":"2020121621255434600_B36","doi-asserted-by":"crossref","first-page":"e000148","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2020121621255434600_B37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"320","key":"2020121621255434600_B38","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"2020121621255434600_B39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"374","key":"2020121621255434600_B40","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"2020121621255434600_B41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"2020121621255434600_B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111531","article-title":"Updated phase 1 results of Zuma-3: Kte-C19, an anti-CD19 chimeric antigen receptor T cell therapy, in adult patients with relapsed\/refractory acute lymphoblastic leukemia [abstract]","volume":"132","author":"Wierda","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020121621255434600_B43","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"355","key":"2020121621255434600_B44","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med."},{"issue":"16","key":"2020121621255434600_B45","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T Cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020121621255434600_B46","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2020.38.15_suppl.8001","article-title":"Phase I Alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL","volume":"38","author":"Osborne","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/487\/1794796\/hem2020000133c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/487\/1794796\/hem2020000133c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:14:07Z","timestamp":1608315247000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/487\/474280\/Chimeric-antigen-receptor-T-cells-for-mature-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000133","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}